Antiviral Discovery for Highly Pathogenic Emerging Viruses
New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state of the art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents.
Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.
Antiviral Discovery for Highly Pathogenic Emerging Viruses, The Royal Society of Chemistry, 2021.
Download citation file:
Digital access
Print format
Table of contents
-
Chapter 1: Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targetsp1-27ByErik De ClercqErik De ClercqKU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical ResearchLeuven 3000Belgium[email protected]Search for other works by this author on:
-
Chapter 2: Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Feversp28-44ByOthmann Merabet;Othmann MerabetUnit of Biology of Emerging Viral Infections, Institut Pasteur21 avenue Tony Garnier69365 Lyon cedex 7France[email protected]Centre International de Recherche en Infectiologie, Lyon I University, INSERM, CNRS, Lyon ENSLyonFranceSearch for other works by this author on:Sylvain BaizeSylvain BaizeUnit of Biology of Emerging Viral Infections, Institut Pasteur21 avenue Tony Garnier69365 Lyon cedex 7France[email protected]Centre International de Recherche en Infectiologie, Lyon I University, INSERM, CNRS, Lyon ENSLyonFranceSearch for other works by this author on:
-
Chapter 3: Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic1p45-60ByCésar Muñoz-Fontela;César Muñoz-FontelaGerman Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-RiemsGermanySearch for other works by this author on:Rafael DelgadoRafael DelgadoInstituto de Investigación Hospital Universitario 12 de Octubre, Universidad Complutense School of MedicineMadridSpainSearch for other works by this author on:
-
Chapter 4: Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses1p61-90ByPatrick Iversen;Patrick IversenUnited States Army Medical Research Institute of Infectious Diseases1425 Porter Street, Fort DetrickMD 21702USA[email protected]Search for other works by this author on:Sandra Bixler;Sandra BixlerUnited States Army Medical Research Institute of Infectious Diseases1425 Porter Street, Fort DetrickMD 21702USA[email protected]Search for other works by this author on:Christopher D. Kane;Christopher D. KaneUnited States Army Medical Research Institute of Infectious Diseases1425 Porter Street, Fort DetrickMD 21702USA[email protected]Search for other works by this author on:Travis K. WarrenTravis K. WarrenUnited States Army Medical Research Institute of Infectious Diseases1425 Porter Street, Fort DetrickMD 21702USA[email protected]Search for other works by this author on:
-
Chapter 5: Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodiesp91-120ByMarc-Antoine de La Vega;Marc-Antoine de La VegaUniversité Laval, Département de microbiologie-infectiologie et d'immunologie, Faculté de médecine2325, Rue de l'UniversitéQuébec City (Québec) G1V 0A6Canada[email protected]Search for other works by this author on:Gary KobingerGary KobingerUniversité Laval, Département de microbiologie-infectiologie et d'immunologie, Faculté de médecine2325, Rue de l'UniversitéQuébec City (Québec) G1V 0A6Canada[email protected]Search for other works by this author on:
-
Chapter 6: Vaccine Development in the Midst of Ebolavirus Disease Outbreaksp121-165ByJakub K. SimonJakub K. SimonSearch for other works by this author on:
-
Chapter 7: Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Virusesp166-184ByTomas CihlarTomas CihlarSearch for other works by this author on:
-
Chapter 8: Therapeutics Against Nipah and Hendra Virusp185-207ByHeinz Feldmann;Heinz FeldmannLaboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health903 South 4th StreetHamiltonMT 59840USA[email protected]Search for other works by this author on:Emmie de WitEmmie de WitLaboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health903 South 4th StreetHamiltonMT 59840USA[email protected]Search for other works by this author on:
-
Chapter 9: Glycomimetics as Promising Inhibitors of Ebola Virus, Flavivirus and HIV Infectionsp208-231ByFranck Fieschi;Franck FieschiUniv. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale38000 GrenobleFrance[email protected][email protected][email protected]Search for other works by this author on:Anna Bernardi;Anna BernardiUniversità degli Studi di Milano, Dipartimento di Chimicavia Golgi 1920133MilanoItalySearch for other works by this author on:Javier RojoJavier RojoUniversidad de Sevilla – CSIC, Instituto de Investigaciones Químicas (IIQ), Glycosystems laboratoryAv. Américo Vespucio 4941092 SevilleSpainSearch for other works by this author on:
-
Chapter 10: Repurposing Approved Drugs to Block Highly Pathogenic Emerging Virusesp232-255ByB. Mercorelli;B. MercorelliUniversity of Padua, Department of Molecular MedicineVia Gabelli 6335121PadovaItaly[email protected]Search for other works by this author on:A. LoregianA. LoregianUniversity of Padua, Department of Molecular MedicineVia Gabelli 6335121PadovaItaly[email protected]Search for other works by this author on:
-
Chapter 11: Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Virusesp256-279ByDaniel Perez-Zsolt;Daniel Perez-ZsoltIrsiCaixa AIDS Research InstituteCtra. de Canyet s/nBadalona 08916Spain[email protected][email protected]Universitat Autònoma de BarcelonaBarcelonaSpainSearch for other works by this author on:Javier Martinez-Picado;Javier Martinez-PicadoIrsiCaixa AIDS Research InstituteCtra. de Canyet s/nBadalona 08916Spain[email protected][email protected]University of Vic-Central University of Catalonia (UVic-UCC)Vic, BarcelonaSpainCatalan Institution for Research and Advanced Studies (ICREA)BarcelonaSpainInstitut d'Investigació en Ciències de la Salut Germans Trias i PujolBadalonaSpainSearch for other works by this author on:Nuria Izquierdo-UserosNuria Izquierdo-UserosIrsiCaixa AIDS Research InstituteCtra. de Canyet s/nBadalona 08916Spain[email protected][email protected]Institut d'Investigació en Ciències de la Salut Germans Trias i PujolBadalonaSpainSearch for other works by this author on:
Spotlight
Advertisement
Advertisement